Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
After the spot Bitcoin ETF began trading, the open contracts of Bitcoin futures on the Chicago Mercantile Exchange fell by about 24%

After the spot Bitcoin ETF began trading, the open contracts of Bitcoin futures on the Chicago Mercantile Exchange fell by about 24%

2024/01/31 06:54

Data compiled by Bloomberg shows that three weeks after the start of trading for 10 spot Bitcoin ETFs, open interest (or outstanding contracts) in CME's Bitcoin futures fell about 24% to 20,679 as of January 30. After soaring 157% last year due to expectations for the ETF, open interest hit a record high. Vetle Lunde, senior analyst at K33 Research, said that investors turning to U.S. ETFs and a cooling off in Bitcoin's rally could lead to "less activity" in CME Bitcoin futures, but they remain key to liquidity in the cryptocurrency market. He pointed out their potential role as hedging tools for authorized participants managing the creation and redemption of ETF units.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss